Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more structured and treatable form—but it gets shut down by an overactive KRAS-driven pathway. When researchers blocked that pathway, GATA6 levels rebounded and cancer cells became more sensitive to chemo. T
The European Medicines Agency's Committee for Medicinal Products for Human Use turned down Acadia's Daybue application for Rett syndrome in late February based on concerns with the company's pivotal trial.
The FDA's decision on a chatbot for patients recovering from surgery could offer clues on how the agency plans to regulate generative AI tools.
A new "Make Europe Healthy Again" movement ties U.S. MAHA figures to European anti-vaccine and far-right networks, raising public health concerns.
6 core challenges that researchers must consider as the race to create models that are ever closer to real human embryos heats up.
CMS said Elevance had "substantial and persistent noncompliance" with requirements to submit information about its customers.
The health insurer paid higher prices for hospital care than some rivals in the ACA insurance market.
As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.
UniQure seeks approval, Novartis settles Henrietta Lacks lawsuit, and more biotech stories
As the effects of the United States and Israel’s weekend attack on Iran begin to ripple through the Middle East, multiple drugmakers operating in the region are taking stock of their local workforces’ safety and committing early to continued medicines access in neighboring countries struck by the unfolding conflict.
Surviving cancer at a young age may come with an unexpected cost: faster aging at both the cellular and brain levels. Researchers found that survivors often show signs of being biologically older than their actual age, with chemotherapy accelerating the process most dramatically. This accelerated aging is linked to struggles with memory and focus, which can ripple into education and career outcome
Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with custom-engineered immune cells that protect them. The goal is to stop the immune system from destroying transplanted cells — without using immunosuppressive drugs. Backed by $1 million in funding, the team hopes to create a ready-to-use treatment that could work even for people who have
The newest additions to the CDC's vaccine advisory committee are Florida internal medicine and pediatrics specialist Sean G. Downing, M.D., and pediatrician Angelina Farella, M.D.
As millions turn to ChatGPT and other AI chatbots for therapy-style advice, new research from Brown University raises a serious red flag: even when instructed to act like trained therapists, these systems routinely break core ethical standards of mental health care. In side-by-side evaluations with peer counselors and licensed psychologists, researchers uncovered 15 distinct ethical risks — from m
Stanley Plotkin, the 93-year-old "godfather of vaccines," is watching his field’s achievements slip away.
HHS's OIG uncovered $285.2 million in improper and potentially improper payments to clinicians of an autism therapy called applied behavior analysis, it said.
What leading health tech firms and AI startups want HHS to do to speed up clinical AI adoption.
Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs, has extended a deal with Ipsen to manufacture Sohonos (palovarotene) capsules. Sohonos is currently the only medication approved by the FDA to treat the ultra-rare disease fibrodysplasia ossificans progressiva.
A tiny wireless implant is giving new hope to people blinded by advanced age-related macular degeneration. In a major international clinical trial, more than 80% of participants regained meaningful central vision, with many able to read letters and even words again after years of decline. The device replaces damaged light-sensing cells in the retina with a 2×2 mm implant that converts light into e
Polyamines—natural molecules found in every living cell—have become stars in the longevity world for their ability to boost cellular cleanup and support healthy aging. But there’s a dark twist: high levels of these same molecules are consistently seen in cancer, where tumors grow aggressively.